Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Growth Hormone Reduces Fractures in Women with Osteoporosis

Will Boggs, MD  |  September 4, 2015

NEW YORK (Reuters Health)—Growth hormone is associated with a decrease in fractures in women with postmenopausal osteoporosis even a decade after treatment ceases, researchers from Sweden report. “We were surprised and pleased to find that the patients had a reduced risk of fracture so many years after the growth hormone treatment was ceased,” Dr. Emily…

Use Behavioral ‘Nudging’ to Tackle Gender, Health Challenges

Joseph D'Urso  |  September 4, 2015

LONDON (Thomson Reuters Foundation)—Many of the world’s biggest challenges, such as encouraging people to buy life-saving drugs or unpicking deeply rooted sexism, can be tackled by using subtle psychological cues to change the way people behave, according to experts in London. Behavioral economics, also known as “nudging,” is about making people more likely to make…

Novartis Launches First U.S. Biosimilar Drug at 15% Discount

Ben Hirschler & Michael Shields  |  September 4, 2015

LONDON/ZURICH (Reuters)—Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first biosimilar copy of a biotechnology drug approved in the U.S., at a discount of 15% to the original. The Swiss drugmaker’s generics unit Sandoz said Zarxio, its form of Amgen’s white blood cell-boosting product Neupogen (filgrastim), would…

Governments Are Not Following Advice on MERS

Tom Miles  |  September 3, 2015

GENEVA (Reuters)—Governments are not doing all they should to tackle the deadly Middle East Respiratory Syndrome, a committee of health experts at the World Health Organization said on Thursday. The WHO’s emergency committee, which meets regularly to consider the international response to the disease, said in a statement that its advice had not been completely…

Resunab Fast Tracked to Treat Scleroderma, Plus, Infliximab Biosimilars in Europe

Michele B. Kaufman, PharmD, BCGP  |  September 2, 2015

The FDA has fast-tracked the development of a drug to treat systemic sclerosis, or scleroderma; initial clinical trials started in June. Also, a major hospital group in France has selected the biosimilar infliximab to treat its patients with RA, Crohn’s disease and psoriasis…

Alcohol Use Complicates Chronic Disease Management in Teens

Will Boggs, MD  |  September 1, 2015

NEW YORK (Reuters Health)—High school students with chronic medical conditions who drink alcohol are more likely than their nondrinking peers to forget or skip taking their medications, according to an online survey. “I was surprised to see such a clear association between alcohol use and medication nonadherence—a finding which really brings home the need to…

Can We Get Closer to a Cure for RA?

Marc Feldmann & Ravinder N. Maini  |  September 1, 2015

Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.

FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs

Reuters Staff  |  August 31, 2015

(Reuters)—A class of diabetes drugs that include Merck & Co Inc.’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006,…

Early, Aggressive Therapy for RA May Result in Cost Savings Long Term

Lara C. Pullen, PhD  |  August 31, 2015

By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…

FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names

Toni Clarke  |  August 28, 2015

WASHINGTON (Reuters)—The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The FDA said its draft guidance is designed to prevent the inadvertent substitution of non-interchangeable products and to make it easier to monitor and track usage once…

  • « Previous Page
  • 1
  • …
  • 563
  • 564
  • 565
  • 566
  • 567
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences